| Private Placement / Financing Transactions
Borealis Biosciences: The company raised $150 million of Series A venture funding from Novartis and Versant Ventures on August 22, 2024. The company is an operator of a discovery-stage biotechnology business developing next-generation xRNA-based medicines for kidney diseases.
Pathalys Pharma: The company raised $105 million of Series B venture funding in a deal led by TCG Crossover Management on August 20, 2024, putting the company’s pre-money valuation at $190 million. DaVita Venture Group, JPMorgan Life Sciences Private Capital, Japan Post Investment, Catalys Pacific, KB Investment, Samsara BioCapital, and Marshall Wace also participated in the round. The company is a developer of advanced therapeutics designed to address unmet needs in the management of late-stage chronic kidney diseases.
Elektrofi: The company raised $96.5 million of Series C venture funding from undisclosed investors on August 22, 2024. The company is a developer of a drug delivery platform intended to improve the subcutaneous administration of biologic therapies through a hyper concentration microparticle platform technology, Hypercon™.
Openwater: The company raised $54 million of venture funding from Bold Capital Partners, Khosla Ventures and Plum Alley Investments on August 22, 2024. Elevation Capital and other undisclosed investors also participated in the round. The company is a developer of a wearable medical device designed to see the inner workings of the body and brain at high resolution.
CeleCor Therapeutics: The company raised $45.5 million of Series B venture funding from undisclosed investors on August 21, 2024. The company is a developer of a novel small molecule inhibitor designed to provide pre-hospital therapies to preserve heart muscle.
XII Medical: The company raised $45 million of Series B venture funding in a deal led by Omega Funds on August 21, 2024, putting the company’s pre-money valuation at $72 million. Cleveland Clinic Ventures, Intuitive Ventures, Broadview Ventures, Aperture Venture Partners, Ajax Health, JobsOhio Growth Capital, and other undisclosed investors also participated in the round. The company is a developer of an implantable neurostimulation device designed to alleviate sleep apnea.
Pictor Labs: The company raised $20.6 million of venture funding from undisclosed investors on August 21, 2024. The company is a developer of a digital imaging platform designed to conduct histopathology.
Earli: The company raised an additional $19 million of Series A-1 venture funding from Accenture Ventures on August 19, 2024, putting the company’s pre-money valuation at $174 million. Other undisclosed investors also participated in the round. The company is a developer of cancer-programmable genetic constructs designed to turn on only in cancer cells and force them to be revealed.
Mend: The company raised $16.5 million of Series A venture funding in a deal led by S2G Ventures on August 19, 2024, putting the company’s pre-money valuation at $41.5 million. Touchdown Ventures, Colorcon, iSelect Fund, Alumni Ventures, Sage Hill Investors, Claridge Venture Partners, Keen Growth Capital and GenHenn Capital also participated in the round. The company is a developer of clinical nutritional and wellness products.
Ambrosia Biosciences: The company raised $16 million of Series A venture funding in a deal led by Boulder Ventures, BVF Partners, and other undisclosed investors on August 20, 2024, putting the company’s pre-money valuation at $14 million. The company is an operator of a drug discovery platform intended to offer small molecule-based therapies for obesity and other metabolic disorders.
Voom Medical Devices: The company raised $15.2 million of Series A venture funding from undisclosed investors on August 22, 2024. The company is a manufacturer of medical equipment for minimally invasive surgery of the foot and ankle.
Switchback Systems: The company raised $11.3 million of venture funding from undisclosed investors on August 21, 2024. The company is an operator of DNA synthesis platform intended to develop technologies that use cell structure as a data storage medium.
Jumpcode Genomics: The company raised $3.4 million of venture funding from undisclosed investors on August 21, 2024. The company is a developer of genome technology designed to improve the sensitivity and reduce cost of next-generation genetic sequencing.
PhotonPharma: The company raised $3 million of Series 2 venture funding from undisclosed investors on August 21, 2024. The company is a developer of a cancer immunotherapy designed to present tumor antigens to the patient, triggering a multi-antigen immune response.
Awen Oncology: The company raised an undisclosed amount of venture funding from the Development Bank of Wales and Start Codon on August 22, 2024. The company is an operator of a pre-clinical oncology drug development business intended to treat malignancies in the healthcare domain.
CancerIQ: The company raised an undisclosed amount of venture funding from Decathlon Capital Partners on August 21, 2024. The company is a developer of a precision health technology designed for doctors to identify and manage patients at high risk for cancer.
Exin Health: The company raised an undisclosed amount of venture funding from Techventure VC and Decacorn Angels on August 21, 2024. The company is a developer of an AI-based surgical platform intended to reduce patient safety risk factors by continuously and objectively observing operating rooms.
Tenza: The company raised an undisclosed amount of venture funding in a deal led by Waveland Group on August 22, 2024. Power Angels also participated in the round. The company is a developer of a novel symbiotic drug-delivery platform designed to employ engineered lactic acid bacteria.
Vonova: The company is in the process of raising venture funding in the form of convertible debt in a deal led by SmartGateVC on August 20, 2024. The company is a developer of catheter-based technology designed to interface with the brain surface for diagnostic and therapeutic applications.
|
